Compare Lufax Holding Ltd (LU) vs 10X Genomics Inc (TXG) Price & Performance

LU trades at $1.36, down 2.16% today. The stock shows a mixed technical picture with a neutral overall signal and bearish moving averages. Fundamentally, the company reported a net loss of $2.1B on $23.1B revenue for 2025, with negative profit margins and returns. Analyst consensus is bullish with 61.5% buy ratings, but sentiment is clouded by multiple class-action lawsuits announced in May 2026 alleging securities fraud.

The outlook is cautious. While low valuation ratios (P/S 0.35, P/B 0.1) and analyst support suggest potential upside, persistent losses and significant legal overhangs pose substantial risks. Investor focus remains on the company's ability to return to profitability amid these challenges.

TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.

The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.